The companies will focus on phage-based products that could help the animal health and food production industries in their struggle to control outbreaks of human pathogenic bacteria such as E coli, Salmonella and Listeria, and the numerous cases of human illness associated with them.
Justin Reber, president and CEO of OmniLytics, said: “The synergies gained through our combined resources have created an exciting partnership by combining the phage expertise of OmniLytics with the product development, market understanding, sales channel, brand and reach of Elanco.”